Search results

197 items matching your search terms.
Filter the results.
Item type













New items since



Sort by relevance · date (newest first) · alphabetically
UNC Lineberger scientist receives grant for pancreatic cancer research
The Lustgarten Foundation, the nation’s largest foundation dedicated solely to funding pancreatic cancer research, has awarded Channing Der, PhD, a $1.165 million grant to identify promising drug combinations for potential future use in clinical trials.
Located in News / 2012 News
UNC Lineberger scientists lead cancer genome analysis of breast cancer
Team identifies genetic causes and similarity to ovarian cancer
Located in News / 2012 News
UNC Lineberger scientists receive grant for pulmonary inflammation research
Three UNC Lineberger researchers are collaborating on a project recently awarded more than $3.3 million over five years from the National Institutes of Health’s National Heart, Lung, and Blood Institute.
Located in News / 2012 News
UNC physician elected to board of directors for American Society for Radiation Oncology
Lawrence B. Marks, MD, has been elected to a two-year term on the Board of Directors of the American Society for Radiation Oncology (ASTRO).
Located in News / 2012 News
UNC radiation oncologists co-author Journal of Clinical Oncology editorial on breast cancer radiotherapy and coronary artery stenosis
Timothy Zagar, MD, assistant professor of radiation oncology, and Lawrence Marks, MD, professor and chair of radiation oncology, co-authored an editorial in the December 27, 2011 issue of the Journal of Clinical Oncology.
Located in News / 2012 News
UNC research center receives contract to fight kidney cancer
The Center for Integrative Chemical Biology and Drug Discovery at the University of North Carolina at Chapel Hill has received a contract from SAIC-Frederick, Inc. to develop potential drug leads for treating renal cell carcinoma, the most common type of kidney cancer in adults.
Located in News / 2012 News
UNC researchers: Benefits of varenicline (Chantix) may balance certain risks
Drs. Christine E. Kistler and Adam Goldstein discuss how clinicians can better have conversations about the balance between short-term risk of adverse cardiovascular events associated with taking Chantix compared to the long-term reduction in the risk of death that results from smoking cessation.
Located in News / 2012 News
UNC scientists collaborate to find first major genetic mutation associated with hereditary prostate cancer risk
Chapel Hill - After a 20-year quest to find a genetic driver for prostate cancer that strikes men at younger ages and runs in families, researchers have identified a rare, inherited mutation linked to a significantly higher risk of the disease.
Located in News / 2012 News
UNC scientists collaborate on colon cancer therapy comparative effectiveness study
In 2008 UNC and Harvard University’s Brigham and Women’s Hospital in Boston were selected by the U.S. Agency for Healthcare Research and Quality to carry out accelerated practical studies examining the comparative effectiveness of cancer treatments. The collaboration is called the Cancer Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) Comparative Effectiveness Consortium.
Located in News / 2012 News
UNC scientists describe protein that protects against colon cancer
Chapel Hill - A family of proteins is yielding new information about how it contributes to the development of gastrointestinal disease and cancer. A team of UNC scientists reports that in pre-clinical models, the absence of a protein called NLRP12 significantly increases susceptibility to colitis-associated colon cancer.
Located in News / 2012 News